Certara, Inc. (NASDAQ:CERT) Shares Sold by Commerce Bank

Commerce Bank reduced its holdings in Certara, Inc. (NASDAQ:CERT) by 5.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,719 shares of the company’s stock after selling 1,628 shares during the quarter. Commerce Bank’s holdings in Certara were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CERT. Blue Trust Inc. acquired a new position in shares of Certara during the 2nd quarter valued at about $26,000. Innealta Capital LLC purchased a new stake in Certara in the second quarter valued at approximately $36,000. KBC Group NV increased its position in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC purchased a new position in Certara during the second quarter worth approximately $152,000. Finally, Algert Global LLC acquired a new position in shares of Certara in the 2nd quarter valued at $156,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 1.1 %

Shares of CERT opened at $10.93 on Wednesday. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The stock’s 50-day moving average is $10.80 and its two-hundred day moving average is $13.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market cap of $1.76 billion, a PE ratio of -54.65, a P/E/G ratio of 5.24 and a beta of 1.51.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS. Equities analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on CERT shares. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Barclays dropped their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $15.92.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.